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Abstract
Introduction In a cross between two mouse strains, the
susceptible B10.RIII (H-2r) and resistant RIIIS/J (H-2r) strains, a
locus on mouse chromosome 5 (Eae39) was previously shown
to control experimental autoimmune encephalomyelitis (EAE).
Recently, quantitative trait loci (QTL), linked to disease in
different experimental arthritis models, were mapped to this
region. The aim of the present study was to investigate whether
genes within Eae39, in addition to EAE, control development of
collagen-induced arthritis (CIA).
Methods CIA, induced by immunisation with bovine type II
collagen, was studied in Eae39  congenic and sub-interval
congenic mice. Antibody titres were investigated with ELISA.
Gene-typing was performed by micro-satellite mapping and
statistics was calculated by standard methods.
Results Experiments of CIA in Eae39  congenic- and sub-
interval congenic mice, carrying RIIIS/J genes on the B10.RIII
genetic background, revealed three loci within Eae39  that
control disease and anti-collagen antibody titres. Two of the loci
promoted disease and the third locus was protected against
CIA development. By further breeding of mice with small
congenic fragments, we identified a 3.2 mega base pair (Mbp)
interval that regulates disease.
Conclusions Disease-promoting and disease-protecting genes
within the Eae39  locus on mouse chromosome 5 control
susceptibility to CIA. A disease-protecting locus in the telomeric
part of Eae39 results in lower anti-collagen antibody responses.
The study shows the importance of breeding sub-congenic
mouse strains to reveal genetic effects on complex diseases.
Introduction
Rheumatoid arthritis (RA) and multiple sclerosis (MS) are com-
plex inflammatory autoimmune disorders in which genetic and
environmental factors contribute to disease development [1].
RA is characterised by peripheral joint inflammation, cartilage
and bone destruction and, subsequently, joint deformation. In
MS, the myelin and axons are affected by inflammation within
the CNS often leading to severe neurological dysfunction. The
disease-causing mechanisms remain unknown, although it is
known that the aetiology is dependent on multiple genetic and
environmental factors. To date, only a few genes have been
associated with susceptibility to RA [2-4] and MS [5,6].
The most commonly used animal model for RA is collagen-
induced arthritis (CIA) [7]. The B10.RIII (H-2r) mouse strain
develops poly-arthritis after immunisation with bovine type II
collagen, whereas the RIIIS/J mouse strain, having the same
major histocompatibility complex (MHC) haplotype (H-2r), is
resistant to poly-arthritis development. Induction of CIA is
dependent on genes within the MHC, but as previously shown
in crosses between B10.RIII and RIIIS/J mice, non-MHC
AUC: area under curve; BSA: bovine serum albumin; CIA: collagen-induced arthritis; CNS: central nervous system; EAE: experimental autoimmune 
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genes also play an important role in susceptibility to disease
[8-10].
Experimental autoimmune encephalomyelitis (EAE) is an
inflammatory demyelinating disease of the central nervous sys-
tem (CNS), widely used as an animal model for MS. The
B10.RIII strain is susceptible to EAE induced by the myelin
basic protein (MBP) peptide 89–101 [11]. From studies of
crosses between B10.RIII and RIIIS/J (resistant to EAE devel-
opment), a number of non-MHC quantitative trait loci (QTLs),
linked to EAE susceptibility, have been reported [12-14]. In
one study, the Eae39 locus on mouse chromosome 5 was
linked to acute EAE [13]. The inheritance pattern showed that
RIIIS/J genes were dominantly protective. The Eae39 locus is
the only QTL linked to EAE on mouse chromosome 5, but six
QTLs linked to disease in arthritis models have been identified
on this chromosome: Cia13,  Cia14  and  Cia27  for CIA
[15,16], Pgia16 for proteoglycan-induced arthritis [17], and
Bbaa3 and Bbaa2 for Borrelia burgdorferi-associated arthritis
[18].
The Eae39 locus was identified as a genetic region of about
30 mega base pairs (Mbp). In order to further investigate the
genetic control of disease in the B10.RIII/RIIIS/J model, we
have studied CIA in Eae39 and Eae39 sub-interval congenic
mice. We observed three different inheritance patterns asso-
ciated with arthritis development, which argues that there are
at least three genes in Eae39 that are important for the devel-
opment of inflammatory disease. Two of the loci, located within
a distance of a few Mbp, contain genes that, depending on the
allele, either protect from or promote disease. This suggests a
balancing effect by closely located genes on disease suscep-
tibility that is revealed when QTLs are split into smaller frag-
ments.
Materials and methods
Animals
C57Bl/10.RIII (B10.RIII) were originally provided by J. Klein
(Tübingen, Germany), and kept in the breeding colony at the
Department of Medical Inflammation Research, Lund Univer-
sity. RIIIS/J animals were purchased from The Jackson Labo-
ratory (Bar Harbor, ME). The Eae39  congenic mice (C1,
Figure 1) were produced by marker selected backcrossing of
the RIIIS/J (donor) mice to the B10.RIII (recipient) strain. All
experiments were approved by the local ethical authorities in
Malmö-Lund, Sweden (permit numbers: M70-04, M75-04,
M107-07 and M109-07).
Induction and evaluation of collagen-induced arthritis
Bovine type II collagen was prepared from calf nasal cartilage
by pepsin digestion and was purified as previously described
[19]. CIA was induced by intra-dermal immunisation at the
base of the mouse's tail with 100 μg bovine CII emulsified in
incomplete Freund's adjuvant (IFA) (Difco, Detroit, MI, USA).
The mice were boosted 35 days later with 50 μg bovine CII
emulsified in IFA. The mice, ranging in age between 10 and 24
weeks, were all immunised the same day. Clinical disease was
monitored once or twice a week according to a scoring system
based on the number of inflamed joints. Each inflamed toe or
knuckle was given a score of one and an inflamed wrist or
ankle was given five points. Each mouse could in total get 15
points per limb and a maximum score of 60. The area under the
curve (AUC) was calculated as the sum of scores for each
individual mouse during a defined test period. The mean max-
imum score, representing disease severity, was calculated as
the mean of the maximum score of all sick mice in the respec-
tive groups.
Antibody measurement
Blood was collected on day 14, 21 or day 54 after immunisa-
tion. Sera were prepared and stored at -20°C until assayed.
ELISA was used to determine levels of antibodies against col-
lagen type II. Plates (Nunc maxisorp, Roskilde, Denmark) were
coated with bovine CII (10 μg/ml) in PBS (pH 9) and blocked
with 1% BSA. Immunoglobulin (Ig) M, IgG1, IgG2c, IgG3 and
total Ig levels were measured using biotinylated secondary
antibodies: goat anti-mouse IgM (No. 1020-08); IgG1
(No.1070-08); IgG2c (No. 1079-04); IgG3 (No. 1100-08);
Figure 1
The Eae39 locus on mouse chromosome 5 The Eae39 locus on mouse chromosome 5. The C1 congenic fragment 
is derived from RIIIS/J and bred on to the B10.RIII background by 
marker selected back-crossing. Black = two B10.RIII alleles; white = 
two RIIIS/J alleles. Mbp = mega base pairs (positions according to 
Ensembl release 49).Available online http://arthritis-research.com/content/11/1/R10
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and total Ig (No. 1010-08) (Southern Biotechnologies Associ-
ates, Birmingham, AL, USA). Binding of biotinylated antibod-
ies was revealed by Extravidin Peroxidase (No. E-2886)
(Sigma-Aldrich, St Louis, MO, USA). Plates were developed
with ABTS: 2,2'-Azino-di-[3-ethylbenzthiazoline sulfonate (6)]
diammonium salt (Roche, Mannheim, Germany). Pooled sera
were used as a standard and the antibody levels were meas-
ured as arbitrary concentrations.
Genotyping and linkage analysis
Genomic DNA was isolated from toe or tail biopsies. The biop-
sies were dissolved in 500 μl of 50 mM sodium hydroxide for
one to two hours at 95°C, and subsequently neutralised with
100 μl 1 mM Tris-HCl (pH 8). To perform a standard 10 μl
PCR, 1 μl of the solution was used. The PCR products were
analysed on a MegaBACE DNA analysis system 1000 (Amer-
sham Pharmacia Biotech, Little Chalfont, UK), according to
the manufacturer's protocol. Fifteen informative fluorescence-
labelled micro-satellite markers (Interactiva Biotechnologie,
Ulm, Germany and MWG Biotech, Ebersberg, Germany) were
used to genotype the Eae39 congenic fragment. Linkage anal-
ysis and permutation tests were conducted as previously
described [13]. Sub-congenic mice were genotyped with
additional micro-satellite markers, where some markers are
made in-house: D5acacbhm4 (114.42 Mbp, forward primer
(FP) 5'-CCCTGTAGAAGACTGGGAATTG-3, reverse primer
(RP) 5'-TCCAGGACAGTCAGGGCTAC-3'), D5taokhm12
(117.53 Mbp, FP: 5'-TCAGGGCTCCATGCACTT-3', RP: 5'-
CACAAGTGGCTCTCAGTGCT-3), D5sdshm18 (120.74
Mbp, FP: 5'-GGGGAACACAAGGAGTTTGA-3', RP: 5'-
ATTCAAGGGCATGTGTGTGA-3').
Results
Eae39 controls collagen-induced arthritis
The Eae39 locus on mouse chromosome 5 (Figure 1) was pre-
viously described in a genetic linkage analysis based on a
backcross between the RIIIS/J and B10.RIII strains [13]. The
confidence interval for Eae39 extended from the micro-satel-
lite marker D5Mit259 (90 Mbp) to D5Mit136 (119 Mbp). This
locus was shown to control incidence of acute EAE in male
mice, with a dominant effect of RIIIS/J alleles on protection
from disease development.
To further investigate the Eae39 locus, a 65 Mbp RIIIS/J frag-
ment was bred into the B10.RIII genome to establish a BR.
Eae39RIIIS/Jcongenic strain (Figure 1). This region contains a
number of QTLs linked to the development of disease in exper-
imental models for arthritis, and we wanted to investigate
whether  Eae39  controls the susceptibility to CIA in the
B10.RIII and RIIIS/J strain combination. Thus, Eae39 congenic
mice were immunised with bovine collagen type II in IFA. As
shown in Figure 2 and Tables 1 and 2, genes within Eae39
control CIA. Figure 2 shows the development of disease in
mice with the congenic Eae39 fragment shown in Figure 1.
Mice with the C1 congenic fragment had higher incidence of
disease (64%) and higher accumulated arthritis score (AUC
(d50-73) = 125 ± 50) compared with the non-congenic litter-
mates (incidence of disease 24%, AUC (d50-73) = 57 ± 29).
(Incidence, p = 0.0271, Chi squared test; AUC (d50-73), p =
0.0379, Mann–Whitney U test).
Next, we intercrossed C1 heterozygous mice in order to get
offspring with overlapping congenic fragments (Figure 3) to
pinpoint smaller intervals within Eae39 linked to the disease
phenotype. The mice were investigated for development of
CIA and each individual was genotyped with markers span-
ning the congenic fragment. We observed that RIIIS/J alleles
at marker D5Mit113 (78 Mbp) promoted disease incidence
(Table 1). In contrast, one RIIIS/J allele at the marker
D5Mit136, in the telomeric part of the fragment, protected
against CIA development (Table 1). There was no difference in
mean maximum score of the affected mice, except for females
with RIIIS/J alleles at marker D5Mit136, which had signifi-
cantly lower CIA scores compared with littermate controls
(Table 1). This is in line with the male mice carrying hetero-
zygous alleles at D5Mit136, where none of the mice devel-
oped arthritis.
In Table 2, correlation between the disease severity phenotype
AUC, day 50 to 73 after immunisation, and genotype is shown.
The AUC is the sum of scores for each individual mouse dur-
ing a defined test period and describes the development of
disease in terms of onset, duration and severity. In line with the
disease incidence data (Table 1), RIIIS/J alleles at D5Mit113
promoted disease, whereas one RIIIS/J allele at about 120
Mbp (D5Mit136, D5Mit367) almost completely protected
from CIA (Table 2). From these results we conclude that
Eae39 harbors genes that, in addition to controlling EAE, are
important for susceptibility to CIA, and that the region contains
Figure 2
Collagen-induced arthritis (CIA) development in mice with the C1 con- genic fragment Collagen-induced arthritis (CIA) development in mice with the C1 con-
genic fragment. a/a (area under the curve (AUC) (d50-73) = 125 ± 50, 
incidence = 64%), b/b (AUC (d50-73) = 57 ± 29, incidence = 24%), 
(AUC (d50-73) p = 0.0379, Mann-Whitney U test, incidence p = 
0.0271, Chi squared test).Arthritis Research & Therapy    Vol 11 No 1    Lindvall et al.
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Table 1
Incidence and mean maximum score of collagen-induced arthritis (CIA) in Eae39 congenic micea
Phenotype Marker Mbpb Group a/ac a/b b/b p-valued
Incidence D5Mit113 77.68 Total 10/14 (71%) 7/12 (58%) 8/42 (19%) 0.0005
Males 3/5 (60%) 4/9 (44%) 2/21 (10%) 0.0222
Females 7/9 (78%) 3/3 (100%) 6/21 (29%) 0.0082
D5Mit136 119.18 Total 11/15 (73%) 3/19 (16%) 11/34 (32%) 0.0019
Males 3/5 (60%) 0/10 (0%) 6/20 (30%) 0.0345
Females 8/10 (80%) 3/9 (33%) 5/14 (36%) 0.0573
Mean max scoree D5Mit113 77.68 Total 23 ± 5 21 ± 5 21 ± 7 0.7766
Males 31 ± 15 20 ± 10 14 ± 2 0.3280
Females 20 ± 5 22 ± 10 24 ± 9 0.9604
D5Mit136 119.18 Total 21 ± 5 6 ± 4 27 ± 15 0.1034
Males 31 ± 15 18 ± 3 0.1948
Females 18 ± 5 6 ± 4 37 ± 6 0.0317
aShows the mean incidence and the mean maximum score of mice with the respective genotypes on markers D5Mit113 and D5Mit136. 
Calculations were made on all mice in Figures 1 and 3 (a to l), and littermate controls. The sub-interval congenic mice were generated by 
intercrossing the C1 congenic mice (Figure 1).
bMbp = mega base pairs. The Mbp position is according to Ensembl release 49.
ca/a = homozygous RIIIS/J alleles; b/b = homozygous B10.RIII alleles; a/b = heterozygous.
dStatistics for incidence was calculated with Chi squared test. Statistics for severity was calculated with Kruskal-Wallis test and Mann-Whitney U 
test.
eMean of the maximum score for all affected mice in Figures 1 and 3.
Table 2
CIA severity in Eae39 congenic mice
AUC (d50-73)a
Marker Mbpb a/ac (n) a/b (n) b/b (n) p-valued
D5Mit113 77.68 126 ± 41 (14) 87 ± 35 (12) 30 ± 15 (42) 0.0006
D5Mit157 101.06 118 ± 39 (15) 41 ± 17 (27) 46 ± 24 (26) 0.0071
D5Mit240 109.52 118 ± 39 (15) 33 ± 16 (27) 55 ± 25 (26) 0.0075
D5Mit136 119.18 118 ± 39 (15) 4 ± 4 (19) 66 ± 22 (34) 0.0023
D5Mit367 120.31 111 ± 37 (16) 5 ± 4 (17) 66 ± 22 (34) 0.0077
D5Mit137 123.73 107 ± 44 (13) 21 ± 13 (22) 68 ± 22 (33) 0.1014
D5Mit95 125.31 99 ± 41 (14) 22 ± 14 (21) 68 ± 22 (33) 0.1799
D5Mit161 127.40 106 ± 44 (13) 24 ± 14 (35) 64 ± 21 (20) 0.2488
D5Mit59 128.20 99 ± 41 (14) 25 ± 15 (19) 66 ± 22 (34) 0.2322
D5Mit31 139.00 125 ± 50 (11) 47 ± 34 (8) 48 ± 16 (49) 0.0423
aArea under curve (AUC) is the mean ± standard error of the total sum of scores for mice with the respective genotypes (day 50 until day 73). All 
mice in Figures 1 and 3 (a to l), and littermate controls (b/b) are included in the calculations. The sub-interval congenic mice were generated by 
intercrossing the C1 congenic mice (Figures 1 and 2).
bMbp = mega base pairs. The Mbp position is according to Ensembl release 49.
ca/a = homozygous RIIIS/J alleles; b/b = homozygous B10.RIII alleles; a/b = heterozygous.
dStatistics calculated with Kruskal-Wallis test.Available online http://arthritis-research.com/content/11/1/R10
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genes operating in different directions in the disease develop-
ment.
In humans, women are more affected by RA than men. The sex
influence on susceptibility to CIA is, however, normally the
opposite in mice. In the first investigation of CIA development
in mice with overlapping Eae39 sub-interval congenic frag-
ments, we observed that female congenic mice had the same,
or slightly higher, incidence of disease compared with male
mice (Table 1). Severity of CIA (mean maximum score) was the
same, except for females homozygous for B10.RIII alleles (b/
b) at marker D5Mit136, in which the severity was higher (p <
0.05) compared with male mice (Table 1). From the original
mapping experiment, Eae39  was linked to development of
acute EAE in male mice [13]. For this reason, and in order to
keep the number of mice used to a minimum, we decided to
continue the present study with male mice only.
The collagen type II antibody response is controlled by 
genes in the Eae39 locus
In an F2 cross between the arthritis susceptible DBA/1J and
the resistant FVB/N strains, it was recently shown that the
Cia27 locus controls anti-collagen type II IgG2a antibody lev-
els [16]. To investigate the corresponding region within the
Eae39 locus for disease phenotypes, we produced mice with
smaller, overlapping congenic fragments (C2 to C5) (Figure 4)
and studied the anti-collagen antibody response after immuni-
sation. The IgG1, IgG2c, IgG3 and IgM anti-collagen serum
levels at day 14 after immunisation were significantly lower in
mice with the C2 congenic fragment (Figure 4) compared with
littermate controls (Table 3). By comparing antibody levels in
mice with the C3 and C4 congenic fragments, we found that
the anti-collagen type II serum titres of the IgG2c isotype were
significantly lower in mice with the C4 fragment compared
with littermates and to mice with the C3 fragment. Mice with
the C5 fragment (spanning from D5Mit317 (112 Mbp) to
D5Mit367 (120 Mbp)) had significantly lower IgG1, IgG2c,
IgG3 and total Ig serum levels compared with littermate con-
trols (Table 3). This confirms the effect on the antibody
response observed with the C2 fragment and shows that
genes in this region control antibody responses to type II col-
lagen.
Collagen-induced arthritis development and antibody 
responses to type II collagen in the C5, C6, C9, C10, and 
C11 congenic mice
Investigation of CIA development in C5 congenic mice
showed that mice with one RIIISJ allele in this interval are pro-
tected from disease development compared with littermate
controls (C5 congenics, incidence = 19%, mean maximum
score = 24 ± 9; littermate controls, incidence = 50%, and
mean maximum score = 31 ± 3; Table 4 and Figure 5b).
To further dissect the C5 region within the Eae39 locus, we
bred congenic mice with overlapping fragments spanning the
C5 region (C6, C9-C11) (Figure 5a). The new congenic mice
were investigated for CIA and antibody responses to type II
collagen. When splitting up the C5 fragment, we observed
Figure 3
Eae39 sub-interval congenic mice Eae39 sub-interval congenic mice. The sub-interval congenic mice were generated by intercrossing heterozygous C1 congenic mice. Black = two 
B10.RIII alleles; white = two RIIIS/J alleles; grey = heterozygous. Mbp = mega base pairs (positions according to Ensembl release 49).Arthritis Research & Therapy    Vol 11 No 1    Lindvall et al.
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two different disease patterns. Mice with the C9 congenic
fragment, which in contrast to C5 does not include the
D5Mit317 marker, had a similar non-severe disease pattern to
mice with the C5 fragment (Table 4, Figure 5d). Mice with the
C6 fragment, covering the centromeric part but lacking the
most telomeric part of the C5 fragment, developed more
severe arthritis compared with mice with the C9 fragment
(Table 4, Figures 5c,d). In mice with the C10 and C11 con-
genic fragments, a different pattern of disease development
was observed because these mice were no longer protected
from CIA, but instead developed more severe disease com-
pared with littermate controls (Figures 5e and 5f, Table 4).
The anti-collagen type II antibody titre was not significantly
lower in mice with the C6 and C9 fragments compared with
the controls (Table 5). In the C10 and C11 congenic mice, the
collagen type II antibody levels followed the disease course
and the antibody concentrations were significantly higher
compared with the littermate controls (Table 5).
In conclusion, when splitting up the C5 fragment into smaller
intervals, we suggest a disease-controlling gene (or genes)
close to the D5Mit317 marker in the upper part of the frag-
ment. This part of C5 is shared with the disease promoting
congenic fragments C10 and C11. Although not statistically
significant for mice with the C6 fragment, the results from the
C6 and C9 congenic mice suggest that a gene conferring pro-
tection against CIA development when one RIIIS/J allele is
present, is located close to the D5Mit136 marker. In contrast
to the C6 fragment, the C9 does not include the promoting
gene/genes around the D5Mit317 marker, which could
explain why the C9 congenic mice are more protected from
disease development. Another possibility would be that there
is another protecting gene close to the D5Mit367 marker,
which is not present in the C6 fragment.
Discussion
This study demonstrates that genes within the Eae39  on
mouse chromosome 5 control development of CIA, and that
this locus contains sub-loci that balance out each other in sus-
ceptibility to disease. By subdividing the original locus into
smaller congenic intervals, we observe stronger effects on the
disease phenotype in either direction. The original locus was
defined in EAE, but here we show that Eae39 additionally con-
trols CIA. Several QTLs for disease development in arthritis
models have been mapped to this region: CIA (Cia13, Cia14
and Cia27) [15,16], proteoglycan-induced arthritis (Pgia16)
[17] and Borrelia burgdorferi-associated arthritis (Bbaa3 and
Bbaa2) [18]. The homologous regions in rats and humans
have been linked to EAE development [20], pristane-induced
arthritis [21], CIA [22] and RA [23,24], MS [25-27] and type
1 diabetes, respectively [28]. This suggests a shared genetic
pathway in autoimmune diseases that is controlled by genes in
this region.
The  Eae39  locus was previously identified in a backcross
between the B10.RIII and RIIIS/J mouse strains and was
shown to control acute EAE in male mice. The inheritance pat-
tern showed that one RIIIS/J allele conferred protection from
EAE [13]. We, and others, have previously demonstrated that
loci linked to the development of polygenic diseases can con-
sist of several sub-QTLs, operating in an additive fashion or in
different directions in the control of the disease trait [9,10,29-
32]. In the present study, we suggest that the original Eae39
locus harbors at least three genes that are involved in disease
development (Figure 6). This could explain why the Eae39
locus was not found in previous EAE and CIA experiments
with B10.RIII/RIIIS/J crosses, where the number of mice did
not allow for the density of genetic recombinations needed to
reveal a disease protecting or enhancing locus [8,14]. Mice
with a small heterozygous Eae39 congenic fragment in the tel-
omeric part of Eae39 were protected from disease. In con-
Figure 4
Schematic outline of congenic fragments in the Eae39 locus Schematic outline of congenic fragments in the Eae39 locus. C2 
(D5Mit412 – D5Mit59); C3 (D5Mit412 – D5Mit317); C4 (D5Mit317 – 
D5Mit95); C5 (D5Mit317 – D5Mit367). The C3 and C4 fragments 
were generated by backcrossing the C2 fragment to the parental 
B10.RIII strain and subsequently intercrossing the offspring. The C5 
fragment was generated by backcrossing the C4 fragment to the 
parental B10.RIII strain and subsequently intercrossing the offspring. 
Black = two B10.RIII alleles; white = two RIIIS/J alleles; grey = hetero-
zygous.Available online http://arthritis-research.com/content/11/1/R10
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trast, homozygous RIIIS/J alleles in the complete Eae39 region
or one RIIIS/J allele at the D5Mit113 (77.7 Mbp) marker, in the
centromeric part of the fragment, promoted disease. This sup-
ports a complex inheritance pattern where RIIIS/J alleles in the
centromeric part of Eae39  promote disease, whereas one
RIIIS/J allele in the telomeric part of Eae39 protects against
disease. The data could be explained by a strong dominant
disease-promoting RIIIS/J gene close to D5Mit113, which
overcomes the effect of the protecting RIIIS/J alleles in the tel-
omeric part of the fragment. We have previously reported a
similar inheritance effect between two QTLs, Cia26  and
Cia30, within the Eae2 locus on mouse chromosome 15 [10].
Splitting up the disease protecting C5 fragment (Figure 5) into
smaller congenic intervals, revealed opposing effects on CIA
development. RIIIS/J alleles in the upper part of C5 (110.1 to
114.6 Mbp) strongly enhanced the disease, whereas mice
carrying congenic fragments including the D5Mit136 marker
(119.8 Mbp) were protected from disease development. The
observation that the C5 fragment, sharing the disease-promot-
ing parts with the C10 and C11 fragments, is protective, could
be explained by a gene close to D5Mit136 that has a stronger
effect on disease compared with the disease promoting gene
located close to D5Mit317. The length of the protective region
is 3.2 Mbp (117.7 to 121.0 Mbp). Except for the nitric oxide
synthase 1 (Nos1), this interval contains no genes known to be
directly involved in inflammation, but includes genes important
in cell signalling, regulation (Taok3, Wsb2, Rfc5, Ksr2, Tesc)
and development (Tbx3, Tbx5, Lhx5).
In addition to studies of CIA development in the Eae39 con-
genic mice, we investigated the antibody response to type II
collagen after immunisation. We observed that the C5 con-
genic mice had lower antibody responses to collagen type II
and were protected from disease development. In contrast,
mice carrying the disease promoting C10 and C11 congenic
fragments had enhanced anti-collagen antibody titres. This
may suggest that the same gene(s) influence anti-collagen
Table 3
Anti-collagen type II antibody responses in C2, C3, C4, and C5 congenic mice
Congenic fragmenta Day after immunisation Antibody isotype a/ab a/bc b/bd p-valuee
C2 14 IgG1 65f ± 7g 115 ± 13 0.0006
IgG2c 80 ± 8 114 ± 12 0.0172
IgG3 97 ± 12 176 ± 25 0.0017
IgM 113 ± 9 171 ± 15 0.0003
C3 54 IgG1 187 ± 30 381 ± 118 0.2667
IgG2c 1468 ± 405 987 ± 373 0.6634
IgG3 238 ± 46 275 ± 62 0.2852
IgM 102 ± 15 155 ± 57 0.4862
C4 54 IgG1 162 ± 57 272 ± 99 0.3465
IgG2c 350 ± 73 797 ± 162 0.0280
IgG3 176 ± 52 214 ± 86 0.4118
IgM 81 ± 9 89 ± 17 >0.999
C5 14 IgG1 139 ± 20 258 ± 37 335 ± 63 0.0172
IgG2c 240 ± 71 368 ± 73 1201 ± 409 0.0076
IgG3 89 ± 18 142 ± 19 189 ± 24 0.0132
IgM 306 ± 68 633 ± 98 875 ± 142 0.0041
aCongenic fragments according to Figure 4.
bMale mice with homozygous RIIIS/J alleles in C3 (n = 22), C4 (n = 12) and C5 (n = 10).
cMale mice with heterozygous alleles in C2 (n = 45) and C5 (n = 10).
dMale mice with homozygous B10.RIII alleles in C2 (n = 28), C3 (n = 9), C4 (n = 8) and C5 (n = 7).
eStatistics was calculated with Mann-Whitney U test and Kruskal-Wallis test.
fArbitrary antibody concentration. Anti-collagen type II antibodies in non-immunised mice are not detectable.
gMean ± standard error of the mean.Arthritis Research & Therapy    Vol 11 No 1    Lindvall et al.
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Figure 5
Collagen-induced arthritis (CIA) in Eae39 congenic mice Collagen-induced arthritis (CIA) in Eae39 congenic mice. (a) A schematic outline of overlapping congenic fragments confined to the C5 interval. Black 
= two B10.RIII alleles; grey = heterozygous. (b - f) CIA development in C5, C6, C9, C10 and C11 congenic mice, and littermate controls. The littermate 
control group comprises all mice homozygous for B10.RIII alleles (b/b) from the breeding of the congenic mice. The different littermate control groups' 
data were pooled because they had similar disease progression. The C5 and C9 congenic fragment have been generated from C4 (Figure 4) by back-
crossing to the B10.RIII parental strain and subsequently intercrossing the offspring. The C6, C10 and C11 were generated by backcrossing C5 con-
genic mice to the B10.RIII parental strain followed by intercrossing of the offspring. Stars indicate significant differences in mean arthritis score: * p < 
0.05, ** p < 0.01.Available online http://arthritis-research.com/content/11/1/R10
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Table 4
CIA phenotypes in C5, C6, C9, C10, and C11 congenic mice
Phenotypea B10.RIIIb C5 B10.RIIIc C6 C9 C10 C11
Incidence 22/44 (50%) 3/17 (19%)* 32/67 (48%) 6/16 (38%) 1/10 (10%)* 10/15 (67%) 14/19 (74%)*
Onsetd 37 ± 2e 49 ± 3 34 ± 2 34 ± 4 36 32 ± 1.5 29 ± 1
Severityf 31 ± 3 24 ± 9 35 ± 3 24 ± 6 24 46 ± 3 48 ± 3*
AUCg 101 ± 20 13 ± 8* 80 ± 13 40 ± 19 10 ± 10* 137 ± 28 166 ± 27**
a Values for incidence, onset, mean maximum score and area under the curve (AUC) are the mean phenotype values for the respective congenic 
mice. The congenic intervals are outlined in Figure 5a. Statistics was calculated with Chi squared test for incidence and Mann-Whitney U test for 
onset, severity and AUC. * p < 0.05, ** p < 0.01.
bB10.RIII = littermate controls for mice with the C5 congenic (a/b) fragment.
cB10.RIII = littermate controls for mice with the C6, C9, C10 and C11 congenic (a/b) fragment.
dThe day for onset of disease.
eMean ± standard error of the mean
fSeverity is the mean of the maximum score of all affected mice in the respective group.
gAUC is the mean of the total sum of scores for mice in the respective group (day 21 to 69).
Table 5
Anti-collagen type II antibody responses in C6, C9, C10 and C11 congenic mice
Antibody isotype B10.RIIIa C6 C9 C10 C11
IgG1 2046b ± 276c 1567 ± 265 1354 ± 193 2520 ± 388* 2868 ± 576*
IgG2c 2337 ± 262 1754 ± 212 2031 ± 420 2859 ± 477 4096 ± 692**
IgG3 1873 ± 141 1364 ± 273 2144 ± 473 2483 ± 370 3021 ± 409**
IgTot 2705 ± 300 2038 ± 291 2439 ± 661 4130 ± 551** 3696 ± 543**
aB10.RIII = littermate controls (n = 64) for mice with the different congenic fragments. The congenic intervals are outlined in Figure 5a. C6 (n = 
14), C9 (n = 9), C10 (n = 15), C11 (n = 17).
bArbitrary antibody concentration in serum. Blood was collected day 21 after immunisation. Anti-collagen type II antibodies in non-immunized mice 
are not detectable.
cMean ± standard error of the mean
Statistics was calculated with Mann-Whitney U test, * p < 0.05, **p < 0.01Arthritis Research & Therapy    Vol 11 No 1    Lindvall et al.
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antibody titres together with the disease phenotype. Interest-
ingly, Yu and colleagues [33] recently reported that the Cia27
locus on mouse chromosome 5 controls anti-collagen IgG2a
antibody titres and the CIA disease phenotype. Although
Cia27 was defined in an arthritis model with a different dis-
ease-inducing protocol and with mouse strains different from
the strains used in the present study, it could be speculated
that the same gene is operating in the two different models.
Cia27 has been confined to 4.1 Mbp, and the peak marker is
located at 120 Mbp, which corresponds to the genetic region
found to control CIA disease phenotypes and anti-collagen
type II antibody responses.
Male mice are normally more susceptible to CIA compared
with female mice. In the present study, Eae39 sub-interval con-
genic female mice had as high an incidence of disease as male
mice. Gender differences in susceptibility to CIA are believed
to be dependent on hormones, genetic factors and behaviour
[34]. We recently reported the identification of QTLs linked to
CIA susceptibility in multiparous female mice [35], but this
study did not reveal any linkage to mouse chromosome 5.
Interestingly, the Eae39 locus includes two genes that are
involved in the effects of oestrogen signalling; the G protein-
coupled oestrogen receptor 1 (Gper, 139.9 Mbp) and oestro-
gen sulfotransferase (Sult1e1, 88.0 Mbp). The studies of
smaller congenic fragments within Eae39  were performed
with male mice and the gender susceptibility was not studied
further. Investigations addressing any role for polymorphisms
between B10.RIII and RIIIS/J in those genes would possibly
contribute to the understanding of gender discrepancies in
susceptibility to CIA.
This study demonstrates that breeding of mice with sub-con-
genic intervals, containing a limited number of genes, is inform-
ative in the dissection of QTLs defined in two-generation-
crosses. Furthermore, it demonstrates that genes within the
same disease pathways are located a close distance apart in
the genome and possibly inherited together. Disease-protec-
tive polymorphisms have balancing effects, while a polymor-
phism in a different genetic context could increase the risk for
disease.
Conclusion
We have located a region in the telomeric part of Eae39 on
mouse chromosome 5 that contains genes that control inci-
dence and severity of CIA and serum levels of anti-collagen
type II antibodies. In addition, we suggest that this region is
influenced by a locus close to the marker D5Mit113 (77.7
Mbp), where B10.RIII alleles together with one RIIIS/J allele at
marker D5Mit136 (119.2 Mbp) result in protection from dis-
ease. The disease-protecting region in the telomeric part of
Eae39 is 3.2 Mbp and includes about 20 genes. Further stud-
ies will focus on the role of the genes within this sub-locus in
the control of inflammatory disease- and sub-phenotypes.
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